Profitability
Weight: 25%
D-
30
- 5yr Avg ROIC -21.5%
- Operating Margin Trend +26.59 pp/yr
AKBA
Akebia Therapeutics, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 23.2 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -308.5%
- 5yr Share-Count CAGR 11.6%
Growth Quality
Weight: 25%
D
34
- 5yr Revenue CAGR 2.8%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -30.6%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
D
39
- Net Debt / EBITDA 1.45x
- Interest Coverage (EBIT/Int) 0.85x
- Altman Z-Score -5.16
Stability
Weight: 5%
B-
65
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 3/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 new buy; 2 added.
- Holders
- 3 +1
- Avg Δ position
- +37.0%
- New buys
- 1
- Full exits
- 0
- Laffont new
- Greenblatt increased +70%
- Cooperman increased +4%